Table 2.
Ten-year MACE outcomes by baseline EPA and DHA quartiles. The mean time to the first MACE was 4.5 ± 3 years.
| EPA | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Unadjusted p-values | Adjusted p-values | |||||
| 10-year outcomes | N = 247 | N = 247 | N = 247 | N = 246 | ||||||
| Follow-up time 8.0 ± 3.2 years | Follow-up time 8.9 ± 2.3 years | Follow-up time 9.0 ± 2.3 years | Follow-up time 9.3 ± 2.1 years | |||||||
| Follow-up time | ||||||||||
| MACE | 100 | 40.5% | 78 | 31.6% | 77 | 31.2% | 56 | 22.8% | 0.0002 | 0.0005 |
| Death | 87 | 35.2% | 61 | 24.7% | 53 | 21.5% | 33 | 13.4% | <0.0001 | 0.0003 |
| MI (>60 days) | 4 | 1.6% | 11 | 4.5% | 7 | 2.8% | 10 | 4.1% | 0.61 | 0.74 |
| Stroke | 15 | 6.1% | 13 | 5.3% | 21 | 8.5% | 13 | 5.3% | 0.26 | 0.84 |
| Heart failure Admission | 11 | 4.5% | 15 | 6.1% | 13 | 5.3% | 8 | 3.3% | 0.15 | 0.26 |
| DHA | ||||||||||
| Q1 | Q2 | Q3 | Q4 | |||||||
| N = 247 | N = 246 | N = 248 | N = 246 | Unadjusted p-values | Adjusted p-values | |||||
| Follow-up time 8.5 ± 2.7 years | Follow-up time 8.7 ± 2.6 years | Follow-up time 8.8 ± 2.5 years | Follow-up time 9.1 ± 2.2 years | |||||||
| MACE | 83 | 33.6% | 80 | 32.5% | 80 | 32.3% | 68 | 27.6% | 0.43 | 0.52 |
| Death | 72 | 29.2% | 63 | 25.6% | 57 | 23.0% | 42 | 17.1% | 0.02 | 0.92 |
| MI (>60 days) | 6 | 2.4% | 9 | 3.7% | 8 | 3.2% | 9 | 3.7% | 0.90 | 0.57 |
| Stroke | 13 | 5.3% | 12 | 4.9% | 25 | 10.1% | 12 | 4.9% | 0.03 | 0.16 |
| Heart failure Admission | 10 | 4.1% | 13 | 5.3% | 11 | 4.4% | 13 | 5.3% | 0.51 | 0.99 |
EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; Q1, first quartile; Q2, second quartile; Q3, third quartile; Q4, forth quartile; MACE, major cardiovascular adverse events; MI, myocardial infarction. The Cox proportional hazard regression model was used for both unadjusted and adjusted p-values. Adjustments were made for age, gender, and significant comorbidities (EPA: hyperlipidemia, COPD, heart failure, and severe CAD; DHA: COPD and PCI performed).